Last updated on December 2019

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease


Brief description of study

The purpose of this program is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Detailed Study Description

This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens for confirmatory evaluation in Phase 3. Participants who complete the 48-week Phase 2 or Phase 3 studies may be eligible to enter the long term extension (LTE). Throughout the 3 studies, efficacy, pharmacokinetic, biomarkers, and safety will be assessed.

Clinical Study Identifier: NCT03466411

Find a site near you

Start Over

Saitama Medical Center

Saitama, Japan
4.48miles
  Connect »

Tokyo Yamate Medical Center

Shinjuku-ku, Japan
7.98miles
  Connect »

Tokyo Yamate Medical Center

Shinjuku-Ku, Japan
7.98miles
  Connect »

Juntendo University Hospital

Bunkyo-Ku, Japan
9.26miles
  Connect »

Juntendo University Hospital

Bunkyo-ku, Japan
9.27miles
  Connect »

Keio University Hospital

Shinjuku-ku, Japan
9.6miles
  Connect »

Keio University Hospital

Shinjuku-Ku, Japan
9.67miles
  Connect »